Nexalin’s Brazil Trial Shows 77.8% Anxiety Response Rate, Boosting Latin American Expansion Plans
Event summary
- Nexalin’s 8-week Brazil trial showed 77.8% anxiety response rate using its DIFS™ 15 mA 77.5 Hz neurostimulation protocol.
- Study participants saw rapid improvements in anxiety, depression, insomnia, and quality of life with benefits maintained at 8-week follow-up.
- No serious adverse events reported, reinforcing Nexalin’s favorable tolerability profile.
- Trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo.
- Company advancing Brazilian sales plan following positive trial results.
The big picture
Nexalin’s successful Brazil trial reinforces its position as a leader in non-invasive neurostimulation, addressing a critical gap in mental health treatment options. The durable benefits across multiple neuropsychiatric domains highlight the potential of its differentiated technology, which could disrupt the neurostimulation market if regulatory and commercial execution align. The company’s focus on expanding in Brazil follows a broader trend of medical device firms targeting high-growth emerging markets to drive revenue.
What we're watching
- Regulatory Pathway
- Whether Nexalin can leverage these results to accelerate its FDA De Novo submission and approval process.
- Market Differentiation
- How Nexalin’s deep-frequency neurostimulation approach will compete against existing neurostimulation technologies.
- Commercial Execution
- The pace at which Nexalin can scale its sales and distribution network in Brazil and other international markets.
Related topics